David A. Dodd to Lead BioReliance Corporation
David A. Dodd has joined BioReliance as the Company's President, Chief Executive Officer and Chairman of the Board, effective December 3, 2007. From 2000 through 2006, Mr. Dodd served as President and CEO of Serologicals Corporation, a publicly traded company that was sold to Millipore Corporation in 2006 for $1.4 billion. Prior to that, from 1995 Mr. Dodd was President and CEO of Solvay Pharmaceuticals, Inc.
Click here to read the press release.
David L. Bellitt joins Bioreliance David L. Bellitt has been named Vice President of Global Commercial Operations, Biologics. Mr. Bellitt will be responsible for all global commercialization activities, including sales, marketing and customer service. He will also serve as a member of the Corporate Operating Committee.
Click here to read the press release.
BioReliance Corporation Launches iNet™ for Online Results Tracking of Biological Safety Tests BioReliance is pleased to announce to US customers the release of iNet, a proprietary information technology system for submitting and tracking test article details via a controlled and secure Internet access from any location worldwide. Now you can view the status of current and past studies, keep informed of when testing will be completed, download reports, and allow your colleagues to view the status of your tests.
Click here to read the press release.